About . . . . . . Classes . . . . . . Books . . . . . . Vita . . . . . . . Links. . . . . . Blog

by Peter Moskos

April 7, 2014

The non-coming of the super-predictor

A nice New York Times video piece about the coming of the "superpredators" who never came. File under C for crack babies?

From the Times:
What happened with the superpredator jeremiads is that they proved to be nonsense. They were based on a notion that there would be hordes upon hordes of depraved teenagers resorting to unspeakable brutality, not tethered by conscience. No one in the mid-1990s promoted this theory with greater zeal, or with broader acceptance, than John J. DiIulio Jr., then a political scientist at Princeton.
DiIulio was also a very good professor, by the way. I got an A in his Politics 240 class.

As John DiIulio says, “Demography is not fate, and criminology is not pure science."

1 comment:

Alex King said...

Tigecycline in vitro antibacterial activity against clinical strains

Abstract: Objective evaluation of tigecycline ( tetracycline antibiotic ) in vitro antibacterial activity against clinical strains . Methods broth dilution method for tigecycline and other 14 kinds of drugs for nearly two years in the hospital clinical specimens of 400 bacteria were isolated MIC determined by WHONET5.4 statistical software . The results showed that MIC determination : tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus showed good antibacterial activity in vitro test has three vancomycin-resistant enterococci (VRE), on behalf of tigecycline and linezolid -sensitive display ;Daptomycin, against Gram- negative bacteria Escherichia coli and ESBL-producing Klebsiella spp MIC ∞ are 1trg · mL ~, behind or below meropenem ; present study for tigecycline against Acinetobacter baumannii

The MIC. (2trg · mL a ) a minimum in all tests of antimicrobial drugs ; against Pseudomonas aeruginosa MIC ∞ value of 16p. g · mL ~.Tigecycline hydrochloride, Conclusion tigecycline against clinical pathogens have good broad-spectrum antimicrobial activity against Pseudomonas aeruginosa Yin poor antibacterial activity.

Tigecycline (tigecycline) is a derivative of minocycline , is the first clinical application of new glycyl doxycycline antibiotics . Intravenous drug formulations, in 2005 the U.S. Food and Drug Administration (FDA) approval : tigecycline for the treatment of patients aged 18 and older infections caused by susceptible strains , indications include : complicated intra-abdominal infections ( such as complicated appendicitis ,Tigecycline mesylate, burns infections, intra-abdominal abscesses, deep soft tissue infections and infected ulcers ) and complicated skin and soft tissue infections. The drug can overcome the limitations of many two main resistance mechanisms of antimicrobial drug use : efflux pumps and ribosomal protection. 1 shows a lot of old literature : the drug can be used to treat multi-drug resistant , such as MRSA, VRE, producing extended-spectrum 13 -lactamase bacterial infections caused by Enterobacteriaceae .Ofloxacin
To understand the in vitro antibacterial activity of the drug , the trial of the 2009 and 2010 clinical isolates from the Ministry of Health, Beijing Hospital, 400 clinical MIC common bacteria were measured to evaluate the in vitro antibacterial activity of the drug .

Medchemexpress Can provide the above product,its website:www.medchemexpress.com